Global /South Korea /Healthcare /Drug Manufacturers - General /293780

AptaBio Therapeutics Inc.

293780

• KRX: 293780 • Delayed

8,470KRW 1.8%

5.61 USD

As of 19 June 2026, AptaBio Therapeutics Inc. has a market cap of $151.62M USD, ranking #22759 globally and #977 in South Korea. It ranks #2041 in the Healthcare sector, and #734 in the Drug Manufacturers - General industry.

Global Rank

22759

Country Rank

977

Sector Rank

2041

Industry Rank

734

Key Stats

Market Cap

$151.62MUSD

233.74B KRW

Enterprise Value

$146.4MUSD

220.97B KRW

Revenue (TTM)

$2.4MUSD

3.7B KRW

EBITDA (TTM)

-$9.97MUSD

-15.06B KRW

Net Income (TTM)

-$10.6MUSD

-16.35B KRW

PS Ratio

63.2

PB Ratio

5.0

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jin Soo open_in_new

Founded

2009

Website

aptabio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.8%	17%	10%	-4.8%	8.8%	-11%	18%	-20%	-73%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	293780 압타바이오(주) Ordinary Shares ISIN: KR7293780003 Shares Out.: Shares Outstanding: 28.093M¹ Shares Float: 19.821M² TV: TradingView: KRX: 293780 SA: Stock Analysis: KRX: 293780 YF: Yahoo Finance: 293780.KS GF: Google Finance: KRX: 293780 BA: Barron's: 293780 MS: Morningstar: XKRX: 293780	8,470 KRW	TV: TradingView: KRX: 293780 SA: Stock Analysis: KRX: 293780 YF: Yahoo Finance: 293780.KS GF: Google Finance: KRX: 293780 BA: Barron's: 293780 MS: Morningstar: XKRX: 293780

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AptaBio Therapeutics Inc.

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells. The company was founded in 2009 and is based in Yongin-si, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.02B 13.91T KRW 6K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.68B 10.3T KRW 4K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.17B 7.97T KRW 3K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.9B 7.55T KRW 3K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.49B 6.92T KRW 3K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.38B 6.76T KRW 3K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 502K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 361K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 238K%	97.4	United States
Roche Holding AG SIX: RO	$321.45B 256.25B CHF 212K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$287.52B 215.59B GBP 190K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.59B 218.9B CHF 181K%	20.5	Switzerland

chevron_leftBack